德展健康(000813.SZ):擬以3780萬元收購德義製藥18%股權
格隆匯9月26日丨德展健康(000813.SZ)公佈,為聚焦醫藥研發主業,優化主營業務板塊佈局,德展大健康股份有限公司於2023年9月25日召開第八屆董事會第十九次會議審議通過了《關於收購德義製藥有限公司18%股權的議案》,同意公司以人民幣3780萬元收購漢義生物科技(北京)有限公司(簡稱“漢義生物”)持有的公司合營企業德義製藥有限公司(簡稱“德義製藥”)18%股權。收購完成後,公司共計持有德義製藥73%股權,德義製藥將納入公司合併報表範圍。本次收購預計將使公司當期財務報表產生約7800萬元投資收益(此為公司財務部門初步預測數據,具體數據以審計機構審計數為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.